Clinical Trials in Ophthalmology: How They Work

Every FDA-approved treatment for glaucoma, macular degeneration, or diabetic retinopathy passed through the same gauntlet: a structured series of clinical trials designed to prove safety and efficacy before a single patient receives a prescription. As of June 2024, ClinicalTrials.gov lists over 14,000 studies tagged under the condition category "Eye Diseases," spanning everything from gene therapies for inherited retinal dystrophies to next-generation intraocular lenses (ClinicalTrials.gov). Understanding how these trials operate — their phases, their design logic, the specific challenges unique to the eye — matters for anyone navigating a diagnosis where the best available option might still be under investigation.

The Phase Structure: From Molecule to Medicine

Clinical trials follow a well-defined progression mandated by the U.S. Food and Drug Administration (FDA). Each phase answers a different question.

Phase I enrolls a small group, typically 20 to 80 participants, and focuses almost entirely on safety. For ophthalmic drugs, this stage determines tolerable dosing for formulations delivered by eye drop, intravitreal injection, or implant. Because the eye is a relatively isolated compartment, systemic side effects can differ dramatically from what animal models predict, making this phase especially informative (FDA – The Drug Development Process).

Phase II expands enrollment to 100–300 participants and begins testing whether the treatment actually works. Researchers select specific outcome measures — often best-corrected visual acuity (BCVA), measured on an Early Treatment Diabetic Retinopathy Study (ETDRS) letter chart, or central retinal thickness on optical coherence tomography (OCT). The landmark MARINA trial for ranibizumab (Lucentis), for instance, used a gain of 15 or more ETDRS letters as a primary endpoint, a standard that shaped wet age-related macular degeneration (AMD) trial design for the next two decades.

Phase III is the large-scale confirmation stage, often enrolling 300 to 3,000+ participants across multiple centers. Regulatory approval hinges on these results. The Phase III VIEW 1 and VIEW 2 trials comparing aflibercept (Eylea) to ranibizumab enrolled a combined 2,457 patients across 362 sites globally (National Eye Institute).

Phase IV, or post-marketing surveillance, tracks real-world outcomes after approval. This phase caught the increased risk of endophthalmitis associated with compounded bevacizumab from certain pharmacies — a safety signal too rare to surface in controlled trials.

Randomization, Masking, and the Sham Injection Problem

Most pivotal ophthalmology trials use randomized, controlled, double-masked designs. Randomization minimizes selection bias; masking prevents both the patient and the examiner from knowing which treatment arm a participant occupies.

Here is where eye trials get interesting — and ethically complex. For intravitreal injection studies, the control group often receives a sham injection: the physician presses a needleless syringe hub against the eye to simulate the sensation of an injection without penetrating the globe. The rationale is that simply visiting a retina clinic and believing one received treatment can influence subjective visual acuity scores. The National Eye Institute (NEI) has funded studies using sham controls for conditions including diabetic macular edema and retinal vein occlusion (NEI Clinical Studies).

Critics have raised concerns about prolonged sham control in diseases with progressive vision loss. Many modern trial protocols address this through rescue criteria — predefined thresholds of worsening that allow control-arm patients to cross over to active treatment.

Ophthalmic-Specific Outcome Measures

The eye offers something unusual in medicine: highly quantifiable functional outcomes. Visual acuity can be measured letter by letter. Intraocular pressure (IOP) can be assessed to the millimeter of mercury. Retinal layer thickness can be mapped in microns.

This precision shapes trial design. The FDA guidance for glaucoma drug trials, for example, specifies that IOP must be measured at multiple time points across the day, because a drug that lowers pressure at 8 a.m. but not at 4 p.m. is clinically inadequate (FDA Guidance for Industry: IOP Endpoints).

For retinal disease trials, structural endpoints from OCT imaging are increasingly accepted as supporting evidence alongside visual acuity. The DRCR Retina Network (formerly the Diabetic Retinopathy Clinical Research Network), funded by NEI, has been instrumental in standardizing these measures across more than 150 participating clinical sites in the United States and Canada (DRCR Retina Network).

Gene Therapy and Adaptive Trial Designs

The 2017 FDA approval of voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophy marked a turning point. That approval rested on a Phase III trial enrolling just 31 participants — possible because the genetic condition is rare and the functional endpoint (a multi-luminance mobility test) was exquisitely sensitive to change (FDA – Luxturna Approval).

Rare-disease ophthalmology trials increasingly use adaptive designs, where interim data analysis allows modifications to dosing, sample size, or patient selection without compromising statistical validity. The FDA's 2019 guidance on adaptive designs explicitly encourages this approach for small-population studies (FDA Adaptive Design Guidance).

How Patients Enter Trials

Eligibility criteria for ophthalmic trials tend to be precise. A wet AMD trial may require a specific lesion size on fluorescein angiography, a BCVA between 20/40 and 20/320, and no prior anti-VEGF treatment in the study eye. These tight criteria improve statistical power but limit generalizability — a tension that every trialist navigates.

Searching for open trials is straightforward. ClinicalTrials.gov allows filtering by condition, location, and recruitment status. The NEI also maintains a directory of trials it funds. Ophthalmologists at academic medical centers typically serve as principal investigators and can screen patients for eligibility during routine visits.

What Happens After the Trial

Trial participants receive follow-up monitoring, but long-term access to an investigational drug is not guaranteed once a study closes — unless the sponsor offers an open-label extension or the FDA grants expanded access. This gap has prompted advocacy groups, particularly in inherited retinal disease communities, to push for clearer post-trial access policies.

The data generated in completed trials becomes part of the public scientific record. Under the FDA Amendments Act of 2007 (FDAAA 801), sponsors must post summary results on ClinicalTrials.gov within one year of completing a trial for most applicable studies (NIH – ClinicalTrials.gov Results Reporting).

References

• ClinicalTrials.gov — U.S. National Library of Medicine
• FDA — The Drug Development Process
• National Eye Institute — Age-Related Macular Degeneration
• NEI Clinical Studies
• FDA Guidance — IOP-Lowering Drugs Efficacy Studies
• DRCR Retina Network
• FDA — Luxturna Approval
• FDA — Adaptive Designs for Clinical Trials Guidance
• NIH — ClinicalTrials.gov Results Reporting

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)